FDA Approved: ULTOMIRIS — Supplemental Application (Alexion Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for ULTOMIRIS (ravulizumab) from Alexion Pharmaceuticals, reflecting an update to labeling or expansion of use.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• ULTOMIRIS (ravulizumab)

Snippet

SUPPL AP for ULTOMIRIS (RAVULIZUMAB)